Bayer AG
https://www.bayer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bayer AG
Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change
Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.
Pepaxto’s Accelerated Approval In Myeloma May Sink On OCEAN Trial's Adverse Survival Data
US FDA is reviewing confirmatory trial data that suggest a ‘detriment in survival’ with Oncopeptides’ alkylating agent in relapsed/refractory multiple myeloma and may convene its Oncologic Drugs Advisory Committee to explore continued marketing for patients who received at least four prior lines of therapy.
Orphan Drugs Dominate EU Fast-Track Request Decisions In July
The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for four potential new orphan treatments.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Asklepios BioPharmaceutical, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis
- Algeta ASA
- Bayer CropScience AG
- Bayer Consumer Care AG
- Berlex Laboratories
- BlueRock Therapeutics
- Conceptus Inc.
- Dihon Pharmaceutical Group Co., Ltd.
- Intendis GmbH
- Jenapharm
- Medrad Inc.
- Possis Medical
- Schering AG
- Monsanto Company
- Zeptosens AG
- KaNDy Therapeutics